People · Operator
Named in public records as an officer, director or promoter · active 2014–2017 · Other Technology, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| theMaven, Inc. | — | Other Technology | Series B | $128.2M | $439.7M | 2017 |
| Pulse Biosciences, Inc. | — | Biotechnology | Series C | $93.0M | $1.4B | 2014 |
| Cue Biopharma, Inc. | — | Biotechnology | Series B | $57.4M | $429.1M | 2015 |
Christopher Marlett at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Marlett on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Amy Wang | 2 | 5 |
| Robert Levande | 2 | 2 |
| Gary Schuman | 2 | 2 |
| David Bailey | 1 | 11 |
| Ross Levinsohn | 1 | 10 |
| Douglas Smith | 1 | 7 |
| Peter Mills | 1 | 5 |
| John Fichthorn | 1 | 5 |
| Doug Smith | 1 | 5 |
| James Heckman | 1 | 5 |
| Cameron Gray | 1 | 4 |
| Peter Kiener | 1 | 4 |
| Anthony DiGiandomenico | 1 | 3 |
| Barry Simon | 1 | 3 |
| Robert Duggan | 1 | 3 |
| Darrin Uecker | 1 | 3 |
| Mahkam Zanganeh | 1 | 3 |
| Peter A. Kiener | 1 | 3 |
| WILLIAM SORNSIN | 1 | 3 |
| Kenneth Clark | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.